Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.77 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.51 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.51 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | TNFRSF1A | P19438 | 4/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | STK3 | Q13188 | 1/20 | 0.47 |
| ▸ | MAP3K9 | P80192 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861572 | 0.91 | MAP2K1 (0.74) | MAP2K1MAP2K2IDO1RAF1PDGFRB | |
| SCHEMBL4860159 | 0.88 | MAP2K1 (0.75) | MAP2K1MAP2K2IDO1AURKATNFRSF1A | |
| SCHEMBL5396163 | 0.87 | MAP2K1 (0.62) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4856761 | 0.87 | MAP2K1 (0.70) | MAP2K1MAP2K2IDO1RAF1PDGFRB | |
| Zapnometinib SCHEMBL29362260 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2IDO1RAF1PDGFRB | |
| Zapnometinib SCHEMBL30298104 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2IDO1RAF1PDGFRB | |
| Zapnometinib SCHEMBL1488782 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2IDO1RAF1PDGFRB | |
| SCHEMBL6945694 | 0.86 | MAP2K1 (0.67) | MAP2K1MAP2K2IDO1RAF1PDGFRB | |
| SCHEMBL23673886 | 0.85 | MAP2K1 (0.67) | MAP2K1MAP2K2IDO1RAF1PDGFRB | |
| SCHEMBL29425507 | 0.85 | MAP2K1 (0.67) | MAP2K1MAP2K2IDO1RAF1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003504400-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1202726-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| EP-1202726-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885IDO1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.